Telix to Host R&D Day in New York City on September 22, 2026
Telix today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City.
Learn about Telix’s theranostics
Leading a new era in cancer care
We are pioneering a theranostic approach that pairs radiopharmaceutical imaging agents and therapeutics to improve patient outcomes across the cancer journey. Our platform is supported by a global manufacturing, supply, and distribution network designed to enable more accessible and personalized care.
Therapeutics
Therapeutics are central to our purpose because of the potential to deliver both improved survival and quality of life. We are advancing a pipeline of targeted therapies across urologic oncology (prostate and kidney), neurologic oncology (brain), and other solid tumors, with the goal of providing more effective and tolerable treatment options tailored to each patient’s disease.
Precision Medicine
We are developing imaging agents to help identify and characterize cancer with greater accuracy. By using the same molecular targets as our therapeutics, our commercial products, Illuccix and Gozellix, and late-stage investigational candidates help physicians better understand who may benefit from specific treatment and guide care across the patient journey.
MedTech
We are advancing surgical solutions, software and AI to enhance the performance of our precision medicines and therapeutics. By integrating these technologies across the care pathway, we aim to help clinicians plan, deliver and monitor treatment with greater efficiency and confidence.
Telix Manufacturing Solutions (TMS)
Telix Manufacturing Solutions is a global network of facilities that enables us to deliver patient doses worldwide. TMS is focused on building manufacturing capacity and developing new technologies to deliver products at scale in a rapidly growing sector.
-
Our Pipeline
One of the most expansive, late-stage research portfolios of diagnostic and therapeutic radiopharmaceutical candidates globally.
Learn more -
Clinical Trials
Our clinical trials are advancing pipeline candidates with the goal of bringing new treatments to patients.
Learn more -
Commercial Products
-
Manufacturing
One of the most expansive, late-stage research portfolios of diagnostic and therapeutic radiopharmaceutical candidates globally.
Learn more
Our clinical trials are advancing pipeline candidates with the goal of bringing new treatments to patients.
Learn more
Explore our imaging agents for men with prostate cancer.
Learn more
Explore Telix’s global network of development and manufacturing facilities.
Learn more
Research & Development
Investor Centre
Careers at Telix
Latest news
Telix H1 2026 Results: Investor Webcast Notification
Telix today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026.
EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer
Telix today announces publication of long‑term clinical outcomes from an investigator‑led study evaluating TLX400‑Tx, its lead fibroblast activation protein (FAP)-targeted therapy candidate, in patients with advanced or metastatic medullary thyroid carcinoma (MTC).
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
Telix today announced publication of results from the ProstACT SELECT study in Cancers, a peer-reviewed journal. The Phase 1 study evaluated TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix’s first-in-class prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy candidate. The study’s scientific purpose was to evaluate lesion concordance between 68Ga-PSMA-PET[5] and multi-time point SPECT[6] imaging for patient selection using a “theranostic” approach.
Latest scientific publications
EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer
Telix today announces publication of long‑term clinical outcomes from an investigator‑led study evaluating TLX400‑Tx, its lead fibroblast activation protein (FAP)-targeted therapy candidate, in patients with advanced or metastatic medullary thyroid carcinoma (MTC).
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
Telix today announced publication of results from the ProstACT SELECT study in Cancers, a peer-reviewed journal. The Phase 1 study evaluated TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix’s first-in-class prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy candidate. The study’s scientific purpose was to evaluate lesion concordance between 68Ga-PSMA-PET[5] and multi-time point SPECT[6] imaging for patient selection using a “theranostic” approach.
PSMA-PET imaging for prostate cancer: Exploring gallium-68 in clinical practice
Telix spoke with a panel of global experts to examine the rapid evolution of gallium-68 (68Ga) PSMA-PET imaging in prostate cancer and to ask where the technology goes next.